Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson’s Disease: Beyond the Primary Mechanism of Action

Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet, 2015, 386(9996), 896-912.
[http://dx.doi.org/10.1016/S0140-6736(14)61393-3] [PMID: 25904081]

Schapira, A.H.V.; Chaudhuri, K.R.; Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci., 2017, 18(7), 435-450.
[http://dx.doi.org/10.1038/nrn.2017.62] [PMID: 28592904]

Poewe, W.; Seppi, K.; Tanner, C.M.; Halliday, G.M.; Brundin, P.; Volkmann, J.; Schrag, A.E.; Lang, A.E. Parkinson disease. Nat. Rev. Dis. Primers, 2017, 3(1), 17013.
[http://dx.doi.org/10.1038/nrdp.2017.13] [PMID: 28332488]

Hiseman, J.P.; Fackrell, R. Caregiver burden and the nonmotor symptoms of Parkinson’s disease. Int. Rev. Neurobiol., 2017, 133, 479-497.
[http://dx.doi.org/10.1016/bs.irn.2017.05.035] [PMID: 28802929]

Aarsland, D.; Brønnick, K.; Fladby, T. Mild cognitive impairment in Parkinson’s disease. Curr. Neurol. Neurosci. Rep., 2011, 11(4), 371-378.
[http://dx.doi.org/10.1007/s11910-011-0203-1] [PMID: 21487730]

Kudlicka, A.; Clare, L.; Hindle, J.V. Executive functions in Parkinson’s disease: Systematic review and meta-analysis. Mov. Disord., 2011, 26(13), 2305-2315.
[http://dx.doi.org/10.1002/mds.23868] [PMID: 21971697]

Emre, M. Dementia in Parkinson’s disease: Cause and treatment. Curr. Opin. Neurol., 2004, 17(4), 399-404.
[http://dx.doi.org/10.1097/01.wco.0000137529.30750.ab] [PMID: 15247534]

Aarsland, D.; Creese, B.; Politis, M.; Chaudhuri, K.R. ffytche, D.H.; Weintraub, D.; Ballard, C. Cognitive decline in Parkinson disease. Nat. Rev. Neurol., 2017, 13(4), 217-231.
[http://dx.doi.org/10.1038/nrneurol.2017.27] [PMID: 28257128]

Matsumoto, M. Dopamine signals and physiological origin of cognitive dysfunction in Parkinson’s disease. Mov. Disord., 2015, 30(4), 472-483.
[http://dx.doi.org/10.1002/mds.26177] [PMID: 25773863]

McGuigan, S.; Zhou, S.H.; Brosnan, M.B.; Thyagarajan, D.; Bellgrove, M.A.; Chong, T.T.J. Dopamine restores cognitive motivation in Parkinson’s disease. Brain, 2019, 142(3), 719-732.
[http://dx.doi.org/10.1093/brain/awy341] [PMID: 30689734]

Pillon, B.; Czernecki, V.; Dubois, B. Dopamine and cognitive function. Curr. Opin. Neurol., 2003, 16(Suppl. 2), S17-S22.
[http://dx.doi.org/10.1097/00019052-200312002-00004] [PMID: 15129846]

Chaudhuri, K.R.; Healy, D.G.; Schapira, A.H.V. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol., 2006, 5(3), 235-245.
[http://dx.doi.org/10.1016/S1474-4422(06)70373-8] [PMID: 16488379]

Armstrong, M.J.; Okun, M.S. Diagnosis and treatment of Parkinson disease. JAMA, 2020, 323(6), 548-560.
[http://dx.doi.org/10.1001/jama.2019.22360] [PMID: 32044947]

Braak, H.; Tredici, K.D.; Rüb, U.; de Vos, R.A.I.; Jansen Steur, E.N.H.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging, 2003, 24(2), 197-211.
[http://dx.doi.org/10.1016/S0197-4580(02)00065-9] [PMID: 12498954]

Buongiorno, M.; Compta, Y.; Martí, M.J. Amyloid-β and τ biomarkers in Parkinson’s disease–dementia. J. Neurol. Sci., 2011, 310(1-2), 25-30.
[http://dx.doi.org/10.1016/j.jns.2011.06.046] [PMID: 21764078]

Siepel, F.J.; Brønnick, K.S.; Booij, J.; Ravina, B.M.; Lebedev, A.V.; Pereira, J.B.; Grüner, R.; Aarsland, D. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson’s disease. Mov. Disord., 2014, 29(14), 1802-1808.
[http://dx.doi.org/10.1002/mds.26051] [PMID: 25284687]

Bohnen, N.I.; Albin, R.L. The cholinergic system and Parkinson disease. Behav. Brain Res., 2011, 221(2), 564-573.
[http://dx.doi.org/10.1016/j.bbr.2009.12.048] [PMID: 20060022]

Liu, A.K.L.; Chang, R.C.C.; Pearce, R.K.B.; Gentleman, S.M. Nucleus basalis of Meynert revisited: Anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol., 2015, 129(4), 527-540.
[http://dx.doi.org/10.1007/s00401-015-1392-5] [PMID: 25633602]

Bocanegra García, Y.; Trujillo Orrego, N.; Pineda Salazar, D.A. Demencia y deterioro cognitivo leve en la enfermedad de Parkinson: Una revisión. Rev. Neurol., 2014, 59(12), 555-569.
[http://dx.doi.org/10.33588/rn.5912.2014082] [PMID: 25501454]

Holland, N.; Robbins, T.W.; Rowe, J.B. The role of noradrenaline in cognition and cognitive disorders. Brain, 2021, 144(8), 2243-2256.
[http://dx.doi.org/10.1093/brain/awab111] [PMID: 33725122]

Riekkinen, M.; Kejonen, K.; Jäkälä, P.; Soininen, H.; Riekkinen, P., Jr Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson’s disease. Eur. J. Neurosci., 1998, 10(4), 1429-1435.
[http://dx.doi.org/10.1046/j.1460-9568.1998.00145.x] [PMID: 9749797]

Ballanger, B.; Strafella, A.P.; van Eimeren, T.; Zurowski, M.; Rusjan, P.M.; Houle, S.; Fox, S.H. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol., 2010, 67(4), 416-421.
[http://dx.doi.org/10.1001/archneurol.2010.35] [PMID: 20385906]

Fox, S.H.; Chuang, R.; Brotchie, J.M. Serotonin and Parkinson’s disease: On movement, mood, and madness. Mov. Disord., 2009, 24(9), 1255-1266.
[http://dx.doi.org/10.1002/mds.22473] [PMID: 19412960]

Cacabelos, R.; Takeda, M.; Winblad, B. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 1999, 14(1), 3-47.
[http://dx.doi.org/10.1002/(SICI)1099-1166(199901)14:1<3:AID-GPS897>3.0.CO;2-7] [PMID: 10029935]

Wesnes, K.A.; Aarsland, D.; Ballard, C.; Londos, E. Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies. Int. J. Geriatr. Psychiatry, 2015, 30(1), 46-54.
[http://dx.doi.org/10.1002/gps.4109] [PMID: 24737460]

Bandini, F.; Pierantozzi, M.; Bodis-Wollner, I. The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson’s disease. A clinical and electrophysiological study. J. Neural Transm. (Vienna), 2002, 109(1), 41-51.
[http://dx.doi.org/10.1007/s702-002-8235-5] [PMID: 11793161]

Fox, S.H.; Katzenschlager, R.; Lim, S.Y.; Barton, B.; de Bie, R.M.A.; Seppi, K.; Coelho, M.; Sampaio, C. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov. Disord., 2018, 33(8), 1248-1266.
[http://dx.doi.org/10.1002/mds.27372] [PMID: 29570866]

Widnell, K. Pathophysiology of motor fluctuations in Parkinson’s disease. Mov. Disord., 2005, 20(S11)(Suppl. 11), S17-S22.
[http://dx.doi.org/10.1002/mds.20459] [PMID: 15822108]

Cilia, R.; Cereda, E.; Akpalu, A.; Sarfo, F.S.; Cham, M.; Laryea, R.; Obese, V.; Oppon, K.; Del Sorbo, F.; Bonvegna, S.; Zecchinelli, A.L.; Pezzoli, G. Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa. Brain, 2020, 143(8), 2490-2501.
[http://dx.doi.org/10.1093/brain/awaa181] [PMID: 32844196]

Espay, A.J.; Morgante, F.; Merola, A.; Fasano, A.; Marsili, L.; Fox, S.H.; Bezard, E.; Picconi, B.; Calabresi, P.; Lang, A.E. Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann. Neurol., 2018, 84(6), 797-811.
[http://dx.doi.org/10.1002/ana.25364] [PMID: 30357892]

Wirdefeldt, K.; Odin, P.; Nyholm, D. Levodopa–carbidopa intestinal gel in patients with Parkinson’s disease: A systematic review. CNS Drugs, 2016, 30(5), 381-404.
[http://dx.doi.org/10.1007/s40263-016-0336-5] [PMID: 27138916]

Jenner, P.; Katzenschlager, R. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat. Disord., 2016, 33(Suppl. 1), S13-S21.
[http://dx.doi.org/10.1016/j.parkreldis.2016.12.003] [PMID: 27979722]

Parkinson Study Group. DATATOP: A multicenter controlled clinical trial in early Parkinson’s disease. Arch. Neurol., 1989, 46(10), 1052-1060.
[http://dx.doi.org/10.1001/archneur.1989.00520460028009] [PMID: 2508608]

Sivertsen, B.; Dupont, E.; Mikkelsen, B.; Mogensen, P.; Rasmussen, C.; Boesen, F.; Heinonen, E. Selegiline and levodopa in early or moderately advanced Parkinson’s disease: A double-blind controlled short- and long-term study. Acta Neurol. Scand., 1989, 80, 147-152.
[http://dx.doi.org/10.1111/j.1600-0404.1989.tb01794.x] [PMID: 2515720]

Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch. Neurol., 2005, 62(2), 241-248.
[http://dx.doi.org/10.1001/archneur.62.2.241] [PMID: 15710852]

Elmer, L.W. Rasagiline adjunct therapy in patients with Parkinson’s disease: Post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat. Disord., 2013, 19(11), 930-936.
[http://dx.doi.org/10.1016/j.parkreldis.2013.06.001] [PMID: 23849501]

Hattori, N.; Takeda, A.; Takeda, S.; Nishimura, A.; Kato, M.; Mochizuki, H.; Nagai, M.; Takahashi, R. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson’s disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism Relat. Disord., 2018, 53, 21-27.
[http://dx.doi.org/10.1016/j.parkreldis.2018.04.025] [PMID: 29748109]

Schapira, A.H.V.; Fox, S.H.; Hauser, R.A.; Jankovic, J.; Jost, W.H.; Kenney, C.; Kulisevsky, J.; Pahwa, R.; Poewe, W.; Anand, R. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations. JAMA Neurol., 2017, 74(2), 216-224.
[http://dx.doi.org/10.1001/jamaneurol.2016.4467] [PMID: 27942720]

Borgohain, R.; Szasz, J.; Stanzione, P.; Meshram, C.; Bhatt, M.; Chirilineau, D.; Stocchi, F.; Lucini, V.; Giuliani, R.; Forrest, E.; Rice, P.; Anand, R. Randomized trial of safinamide add‐on to levodopa in Parkinson’s disease with motor fluctuations. Mov. Disord., 2014, 29(2), 229-237.
[http://dx.doi.org/10.1002/mds.25751] [PMID: 24323641]

Hattori, N.; Tsuboi, Y.; Yamamoto, A.; Sasagawa, Y.; Nomoto, M. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled, phase II/III study. Parkinsonism Relat. Disord., 2020, 75, 17-23.
[http://dx.doi.org/10.1016/j.parkreldis.2020.04.012] [PMID: 32446176]

Gray, R.; Patel, S.; Ives, N.; Rick, C.; Woolley, R.; Muzerengi, S.; Gray, A.; Jenkinson, C.; McIntosh, E.; Wheatley, K.; Williams, A.; Clarke, C.E.; Young, K.; Price, H.; Price, J.; Lambert, A.; Reeve, R.; Sewell, M.; Broome, S.; Williams, A.; Baker, M.; Clarke, C.; Fitzpatrick, R.; Gray, A.; Greenhall, R.; Jenkinson, C.; Mant, D.; McIntosh, E.; Sandercock, P.; Baugent, C.; Crome, P.; Au, P.; Boodell, T.; Cheed, V.C.; Daniels, J.; Dowling, F.; Evans, L.; Hawker, R.; Kaur, S.; Rick, C.; Wheatley, K.; Winkles, N.; Hingley, D.; Sturdy, L.; Wooley, R.; Ottridge, R.; Peto, L.; Hilken, N.; Counsell, C.; Caie, L.; Caslake, R.; Coleman, R.; Crowley, P.; Gerrie, L.; Gordon, J.; Harris, C.; Leslie, V.; MacLeod, M.A.; Taylor, K.; Worth, P.; Barker, R.A.; Forsyth, D.; Halls, M.; Young, J.; Phillips, W.; Manford, M.; Thangarajah, N.; Blake, D.; Prescott, R.; Carr, P.; Cochrane, L.; Rose, A.; McLaren, A.; Drover, M.; Karunaratne, P.; Eady, A.; Wislocka-Kryjak, M.; Ghaus, N.; Grueger, A.; Mallinson, B.; Wihl, G.; Ballantyne, S.; Hutchinson, S.; Lewthwaite, A.; Nicholl, D.; Ritch, A.; Coyle, S.; Hornabrook, R.; Irfan, H.; Poxon, S.; Nath, U.; Davison, J.; Dodds, S.; Robinson, G.; Gray, C.; Fletcher, P.; Morrow, P.; Sliva, M.; Folkes, E.; Gilbert, A.; Hayes, H.; Burrows, E.; Donaldson, S.; Lawrence, J.; Rhind, G.; Baxter, G.; Bell, J.; Gorman, J.; Guptha, S.; Noble, C.; Hindle, J.; Jones, S.; Ohri, P.; Subashchandran, R.; Roberts, E.; Raw, J.; Wadhwa, U.; Aspden, L.; Partington, L.; Vanek, H.; Whone, A.; Barber, R.; Haywood, B.; Heywood, P.; Lewis, H.; O’Sullivan, K.; Prout, K.; Whelan, L.; Medcalf, P.; Sliva, M.; Fuller, G.; Morrish, P.; Wales, E.; Dalziel, J.; Overstall, P.; Bouifraden, K.; Evans, C.; Ward, G.; Matheson, P.; Lockington, T.; Graham, A.; Grimmer, S.F.M.; Sheehan, L.J.; Williams, H.; Hubbard, I.; Walters, R.; Glasspool, R.; Critchley, P.; Abbott, R.; Kendall, B.; Lawden, M.; Lo, N.; Rajaally, Y.; Simpson, B.; Martey, J.; Wray, L.G.; Omar, M.; Sharma, A.; Gale, A.; Phirii, D.; Sekaran, L.; Wijayasiri, S.; Silverdale, M.; Walker, D.; Fleary, H.; Monaghan, A.; Senthil, V.; Reynolds, S.; Chong, M.S.; Diem, D.; Kundu, B.; Arnold, D.; Quinn, N.; Benamer, H.; Billings, J.; Corston, R.; D’Costa, D.; Green, M.; Shuri, J.; Noble, J.M.; Cassidy, T.; Gani, A.; Lawson, R.; Nirubin, A.; Cochius, J.; Dick, D.; Lee, M.; Payne, B.; Roche, M.; Sabanathan, K.; Shields, S.; Hipperson, M.; Reading, F.; Saunders, J.; Harper, G.; Honan, W.; Gill, L.; Stanley, J.; Vernon, N.; Skinner, A.; McCann, P.; Walker, R.; Edmonds, P.; O’Hanlon, S.; Wood, B.; Hand, A.; Robinson, L.; Liddle, J.; Bolam, D.; Raha, S.; Ebebezer, L.; Thompson, S.; Pall, H.; Praamstra, P.; Crouch, R.; Healy, K.; Johnson, M.; Jenkinson, M.; Abdel-Hafiz, A.; Al-Modaris, F.; Dutta, S.; Mallik, T.; Mondal, B.; Roberts, J.; Sinha, S.; Amar, K.; Atkins, S.; Devadason, G.; Martin, A.; Cox, C.; Malone, T.; Fenwick, G.; Gormley, K.; Gutowski, N.; Harris, S.; Harrower, T.; Hemsley, A.; James, M.; Jeffreys, M.O.; Pearce, V.; Sheridan, R.; Sword, J.; Zeman, A.; Soper, C.; Vassallo, J.; Bennett, J.; Lyell, V.; Robertson, D.; Howcroft, D.; Mugweni, K.; Stephens, A.; Whelan, E.; Wright, A.; Chamberlain, J.; Padiachy, D.; Marigold, J.; Lee, J.; Roberts, H.; Adams, J.; Dulay, J.; Evans, S.; Frankel, J.; Gove, R.; Turner, G.; Mallik, N.; McElwaine, T.; Morgan, S.; Phipps, H.; Pressly, V.; Queen, V.; Tan, R.; Grossett, D.; Macphee, G.; Vennard, C.; Rektorova, I.; Dhakam, Z.; Carey, G.; Castledon, B.; Sunderland, C.; Kalcantera, E.; Long, C.; Mandal, B.; Martin, V.; Nari, R.; Nicholas, V.; Moffitt, V.; Hammans, S.; Rice-Oxley, M.; Webb, J.; Franks, S.; Cooper, S.; Hussain, M.; Solanki, T.; Darch, W.; Homan, J.; Sharratt, D.; Griggs, G.; Kendall, G.; Ford, A.; Stocker, K.; Strens, L.; Grubneac, A.; Ponsford, J.; Teare, L.; Moore, A.P.; O’Brien, I.; Watling, D.; Wyatt, L.; Rizvi, S.; Walker, E.; Berry, G.; Russell, N.; Rashed, K.; Baker, K.; Qadiri, M.R.; Buckley, C.; Bulley, S.; Gibbons, D.; Goodland, R.; Heywood, P.; Jones, L.; Martin, L.; Rowland-Axe, R.; Stone, A.; Whittuck, M.R. Long-term effectiveness of adjuvant treatment with catechol-O-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by levodopa therapy. JAMA Neurol., 2022, 79(2), 131-140.
[http://dx.doi.org/10.1001/jamaneurol.2021.4736] [PMID: 34962574]

Csanda, E.; Tárczy, M. Selegiline in the early and late phases of Parkinson’s disease. J. Neural Transm. Suppl., 1987, 25, 105-113.
[PMID: 3123597]

Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch. Neurol., 2002, 59(12), 1937-1943.
[http://dx.doi.org/10.1001/archneur.59.12.1937] [PMID: 12470183]

Jankovic, J.; Berkovich, E.; Eyal, E.; Tolosa, E. Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: Post-hoc analyses from the ADAGIO trial. Parkinsonism Relat. Disord., 2014, 20(6), 640-643.
[http://dx.doi.org/10.1016/j.parkreldis.2014.02.024] [PMID: 24637126]

Magyar, K. The pharmacology of selegiline. Int. Rev. Neurobiol., 2011, 100, 65-84.
[http://dx.doi.org/10.1016/B978-0-12-386467-3.00004-2] [PMID: 21971003]

Alborghetti, M.; Nicoletti, F. Different generations of type-B monoamine oxidase inhibitors in Parkinson’s disease: From bench to bedside. Curr. Neuropharmacol., 2019, 17(9), 861-873.
[http://dx.doi.org/10.2174/1570159X16666180830100754] [PMID: 30160213]

Hietanen, M.H. Selegiline and cognitive function in Parkinson’s disease. Acta Neurol. Scand., 1991, 84(5), 407-410.
[http://dx.doi.org/10.1111/j.1600-0404.1991.tb04978.x] [PMID: 1776388]

Dalrymple-Alford, J.C.; Jamieson, C.F.; Donaldson, I.M. Effects of selegiline (deprenyl) on cognition in early Parkinson’s disease. Clin. Neuropharmacol., 1995, 18(4), 348-359.
[http://dx.doi.org/10.1097/00002826-199508000-00007] [PMID: 8665548]

Murakami, H.; Momma, Y.; Nohara, T.; Mori, Y.; Futamura, A.; Sugita, T.; Ishigaki, S.; Katoh, H.; Kezuka, M.; Ono, K.; Miller, M.W.; Kawamura, M. Improvement in language function correlates with gait improvement in drug-naïve Parkinson’s disease patients taking dopaminergic medication. J. Parkinsons Dis., 2016, 6(1), 209-217.
[http://dx.doi.org/10.3233/JPD-150702] [PMID: 26889633]

Portin, R.; Rinne, U.K. The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment. Acta Neurol. Scand., 1983, 68, 135-144.
[http://dx.doi.org/10.1111/j.1600-0404.1983.tb01528.x] [PMID: 6428146]

Barone, P.; Santangelo, G.; Morgante, L.; Onofrj, M.; Meco, G.; Abbruzzese, G.; Bonuccelli, U.; Cossu, G.; Pezzoli, G.; Stanzione, P.; Lopiano, L.; Antonini, A.; Tinazzi, M. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non‐demented Parkinson’s disease patients. Eur. J. Neurol., 2015, 22(8), 1184-1191.
[http://dx.doi.org/10.1111/ene.12724] [PMID: 25962410]

Hanagasi, H.A.; Gurvit, H.; Unsalan, P.; Horozoglu, H.; Tuncer, N.; Feyzioglu, A.; Gunal, D.I.; Yener, G.G.; Cakmur, R.; Sahin, H.A.; Emre, M. The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study. Mov. Disord., 2011, 26(10), 1851-1858.
[http://dx.doi.org/10.1002/mds.23738] [PMID: 21500280]

Rinaldi, D.; Assogna, F.; Sforza, M.; Tagliente, S.; Pontieri, F.E. Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: A pilot study. Neurol. Sci., 2018, 39(1), 141-143.
[http://dx.doi.org/10.1007/s10072-017-3123-2] [PMID: 28956175]

Weintraub, D.; Hauser, R.A.; Elm, J.J.; Pagan, F.; Davis, M.D.; Choudhry, A. Rasagiline for mild cognitive impairment in Parkinson’s disease: A placebo-controlled trial. Mov. Disord., 2016, 31(5), 709-714.
[http://dx.doi.org/10.1002/mds.26617] [PMID: 27030249]

Frakey, L.L.; Friedman, J.H. Cognitive effects of rasagiline in mild-to-moderate stage Parkinson’s disease without dementia. J. Neuropsychiatry Clin. Neurosci., 2017, 29(1), 22-25.
[http://dx.doi.org/10.1176/appi.neuropsych.15050118] [PMID: 27829318]

Salvati, P.; Maj, R.; Caccia, C.; Cervini, M.A.; Fornaretto, M.G.; Lamberti, E.; Pevarello, P.; Skeen, G.A.; White, H.S.; Wolf, H.H.; Faravelli, L.; Mazzanti, M.; Mancinelli, E.; Varasi, M.; Fariello, R.G. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J. Pharmacol. Exp. Ther., 1999, 288(3), 1151-1159.
[PMID: 10027853]

Morari, M.; Brugnoli, A.; Pisanò, C.A.; Novello, S.; Caccia, C.; Melloni, E.; Padoani, G.; Vailati, S.; Sardina, M. Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia. J. Pharmacol. Exp. Ther., 2018, 364(2), 198-206.
[http://dx.doi.org/10.1124/jpet.117.245100] [PMID: 29167350]

Onofrj, M.; Bonanni, L.; Thomas, A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin. Investig. Drugs, 2008, 17(7), 1115-1125.
[http://dx.doi.org/10.1517/13543784.17.7.1115] [PMID: 18549347]

Conn, P.J.; Battaglia, G.; Marino, M.J.; Nicoletti, F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci., 2005, 6(10), 787-798.
[http://dx.doi.org/10.1038/nrn1763] [PMID: 16276355]

Cattaneo, C.; Sardina, M.; Bonizzoni, E. Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson’s disease fluctuating patients: Post hoc analysesof studies 016 and SETTLE. J. Parkinsons Dis., 2016, 6(1), 165-173.
[http://dx.doi.org/10.3233/JPD-150700] [PMID: 26889632]

Borgohain, R.; Szasz, J.; Stanzione, P.; Meshram, C.; Bhatt, M.H.; Chirilineau, D.; Stocchi, F.; Lucini, V.; Giuliani, R.; Forrest, E.; Rice, P.; Anand, R. Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson’s disease. Mov. Disord., 2014, 29(10), 1273-1280.
[http://dx.doi.org/10.1002/mds.25961] [PMID: 25044402]

Abbruzzese, G.; Kulisevsky, J.; Bergmans, B.; Gomez-Esteban, J.C.; Kägi, G.; Raw, J.; Stefani, A.; Warnecke, T.; Jost, W.H. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SYNAPSES Trial1. J. Parkinsons Dis., 2021, 11(1), 187-198.
[http://dx.doi.org/10.3233/JPD-202224] [PMID: 33104040]

Cattaneo, C.; Müller, T.; Bonizzoni, E.; Lazzeri, G.; Kottakis, I.; Keywood, C. Long-term effects of safinamide on mood fluctuations in Parkinson’s disease. J. Parkinsons Dis., 2017, 7(4), 629-634.
[http://dx.doi.org/10.3233/JPD-171143] [PMID: 28777756]

Cattaneo, C.; Barone, P.; Bonizzoni, E.; Sardina, M. Effects of safinamide on pain in fluctuating Parkinson’s disease patients: A post-hoc analysis. J. Parkinsons Dis., 2017, 7(1), 95-101.
[http://dx.doi.org/10.3233/JPD-160911] [PMID: 27802242]

Cattaneo, C.; Kulisevsky, J.; Tubazio, V.; Castellani, P. Long-term efficacy of safinamide on Parkinson’s disease chronic pain. Adv. Ther., 2018, 35(4), 515-522.
[http://dx.doi.org/10.1007/s12325-018-0687-z] [PMID: 29542008]

Liguori, C.; Mercuri, N.B.; Stefani, A.; Pierantozzi, M. Effective treatment of restless legs syndrome by safinamide in Parkinson’s disease patients. Sleep Med., 2018, 41, 113-114.
[http://dx.doi.org/10.1016/j.sleep.2017.09.017] [PMID: 29268951]

Bianchi, M.L.E.; Riboldazzi, G.; Mauri, M.; Versino, M. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease. Neurol. Sci., 2019, 40(2), 275-279.
[http://dx.doi.org/10.1007/s10072-018-3628-3] [PMID: 30382437]

De Micco, R.; Satolli, S.; Siciliano, M.; De Mase, A.; Giordano, A.; Tedeschi, G.; Tessitore, A. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: A prospective longitudinal study. Neurol. Sci., 2022, 43(1), 357-364.
[http://dx.doi.org/10.1007/s10072-021-05324-w] [PMID: 34031800]

Rinaldi, D.; Sforza, M.; Assogna, F.; Savini, C.; Salvetti, M.; Caltagirone, C.; Spalletta, G.; Pontieri, F.E. Safinamide improves executive functions in fluctuating Parkinson’s disease patients: An exploratory study. J. Neural Transm. (Vienna), 2021, 128(2), 273-277.
[http://dx.doi.org/10.1007/s00702-020-02259-y] [PMID: 33068177]

Bundgaard, C.; Montezinho, L.P.; Anderson, N.; Thomsen, C.; Mørk, A. Selegiline induces a wake promoting effect in rats which is related to formation of its active metabolites. Pharmacol. Biochem. Behav., 2016, 150-151, 147-152.
[http://dx.doi.org/10.1016/j.pbb.2016.10.003] [PMID: 27984094]

Yasar, S.; Goldberg, J.P.; Goldberg, S.R. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J. Neural Transm. Suppl., 1996, 48, 61-73.
[http://dx.doi.org/10.1007/978-3-7091-7494-4_6] [PMID: 8988462]

Biundo, R.; Weis, L.; Antonini, A. Cognitive decline in Parkinson’s disease: The complex picture. NPJ Parkinsons Dis., 2016, 2(1), 16018.
[http://dx.doi.org/10.1038/npjparkd.2016.18] [PMID: 28725699]

Narayanan, N.S.; Rodnitzky, R.L.; Uc, E.Y. Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Rev. Neurosci., 2013, 24(3), 267-278.
[http://dx.doi.org/10.1515/revneuro-2013-0004] [PMID: 23729617]

Borovac, J.A. Side effects of a dopamine agonist therapy for Parkinson’s disease: A mini-review of clinical pharmacology. Yale J. Biol. Med., 2016, 89(1), 37-47.
[PMID: 27505015]

Fenu, S.; Wardas, J.; Morelli, M. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson’s disease. Behav. Pharmacol., 2009, 20(5-6), 363-379.
[http://dx.doi.org/10.1097/FBP.0b013e32833109a0] [PMID: 19724195]

Martinez-Martin, P.; Wan, Y.M.; Ray Chaudhuri, K.; Schrag, A.E.; Weintraub, D. Impulse control and related behaviors in Parkinson’s disease with dementia. Eur. J. Neurol., 2020, 27(6), 944-950.
[http://dx.doi.org/10.1111/ene.14169] [PMID: 32048392]

Anderson, K.E. Behavioral disturbances in Parkinson’s disease. Dialogues Clin. Neurosci., 2004, 6(3), 323-332.
[http://dx.doi.org/10.31887/DCNS.2004.6.3/kanderson] [PMID: 22033600]

Trojano, L.; Papagno, C. Cognitive and behavioral disorders in Parkinson’s disease: An update. II: Behavioral disorders. Neurol. Sci., 2018, 39(1), 53-61.
[http://dx.doi.org/10.1007/s10072-017-3155-7] [PMID: 29038946]

Merims, D.; Giladi, N. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson’s disease. Parkinsonism Relat. Disord., 2008, 14(4), 273-280.
[http://dx.doi.org/10.1016/j.parkreldis.2007.09.007] [PMID: 17988927]

Antonelli, F.; Strafella, A.P. Behavioral disorders in Parkinson’s disease: The role of dopamine. Parkinsonism Relat. Disord., 2014, 20(Suppl. 1), S10-S12.
[http://dx.doi.org/10.1016/S1353-8020(13)70005-1] [PMID: 24262157]

Nyholm, D.; Jost, W.H. An updated calculator for determining levodopa-equivalent dose. Neurol. Res. Pract., 2021, 3(1), 58.
[http://dx.doi.org/10.1186/s42466-021-00157-6] [PMID: 34689840]

Verber, D.; Novak, D.; Borovič, M.; Dugonik, J.; Flisar, D. EQUIDopa: A responsive web application for the levodopa equivalent dose calculator. Comput. Methods Programs Biomed., 2020, 196, 105633.
[http://dx.doi.org/10.1016/j.cmpb.2020.105633] [PMID: 32653677]

Schade, S.; Mollenhauer, B.; Trenkwalder, C. Levodopa equivalent dose conversion factors: An updated proposal including opicapone and safinamide. Mov. Disord. Clin. Pract. (Hoboken), 2020, 7(3), 343-345.
[http://dx.doi.org/10.1002/mdc3.12921] [PMID: 32258239]

Geroin, C.; Di Vico, I.A.; Squintani, G.; Segatti, A.; Bovi, T.; Tinazzi, M. Effects of safinamide on pain in Parkinson’s disease with motor fluctuations: An exploratory study. J. Neural Transm. (Vienna), 2020, 127(8), 1143-1152.
[http://dx.doi.org/10.1007/s00702-020-02218-7] [PMID: 32572581]

Gómez-López, A.; Sánchez-Sánchez, A.; Natera-Villalba, E.; Ros-Castelló, V.; Beltrán-Corbellini, Á.; Fanjul-Arbós, S.; Pareés, M.I.; López-Sendon Moreno, J.L.; Martínez Castrillo, J.C.; Alonso-Canovas, A. SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease. Brain Sci., 2021, 11(1), 57.
[http://dx.doi.org/10.3390/brainsci11010057] [PMID: 33418858]

Gardoni, F.; Morari, M.; Kulisevsky, J.; Brugnoli, A.; Novello, S.; Pisanò, C.A.; Caccia, C.; Mellone, M.; Melloni, E.; Padoani, G.; Sosti, V.; Vailati, S.; Keywood, C. Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia. J. Pharmacol. Exp. Ther., 2018, 367(3), 442-451.
[http://dx.doi.org/10.1124/jpet.118.251645] [PMID: 30291173]

Morin, N.; Morissette, M.; Grégoire, L.; Di Paolo, T. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias. Curr. Neuropharmacol., 2016, 14(5), 481-493.
[http://dx.doi.org/10.2174/1570159X14666151201185652] [PMID: 26639458]

Litim, N.; Morissette, M.; Di Paolo, T. Metabotropic glutamate receptors as therapeutic targets in Parkinson’s disease: An update from the last 5 years of research. Neuropharmacology, 2017, 115, 166-179.
[http://dx.doi.org/10.1016/j.neuropharm.2016.03.036] [PMID: 27055772]

Calabresi, P.; Giacomini, P.; Centonze, D.; Bernardi, G. Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity? Ann. Neurol., 2000, 47(4)(Suppl. 1), S60-S68.
[PMID: 10762133]

Tozzi, A.; Sciaccaluga, M.; Loffredo, V.; Megaro, A.; Ledonne, A.; Cardinale, A.; Federici, M.; Bellingacci, L.; Paciotti, S.; Ferrari, E.; La Rocca, A.; Martini, A.; Mercuri, N.B.; Gardoni, F.; Picconi, B.; Ghiglieri, V.; De Leonibus, E.; Calabresi, P. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit. Brain, 2021, 144(11), 3477-3491.
[http://dx.doi.org/10.1093/brain/awab242] [PMID: 34297092]

Guerra, A.; Suppa, A.; D’Onofrio, V.; Di Stasio, F.; Asci, F.; Fabbrini, G.; Berardelli, A. Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson’s disease. Brain Stimul., 2019, 12(6), 1517-1525.
[http://dx.doi.org/10.1016/j.brs.2019.06.012] [PMID: 31217080]

Guerra, A.; Asci, F.; Zampogna, A.; D’Onofrio, V.; Suppa, A.; Fabbrini, G.; Berardelli, A. Long-term changes in short-interval intracortical facilitation modulate motor cortex plasticity and L-dopa-induced dyskinesia in Parkinson’s disease. Brain Stimul., 2022, 15(1), 99-108.
[http://dx.doi.org/10.1016/j.brs.2021.11.016] [PMID: 34823038]